MX362059B - Derivados de carbamato/urea. - Google Patents
Derivados de carbamato/urea.Info
- Publication number
- MX362059B MX362059B MX2015000903A MX2015000903A MX362059B MX 362059 B MX362059 B MX 362059B MX 2015000903 A MX2015000903 A MX 2015000903A MX 2015000903 A MX2015000903 A MX 2015000903A MX 362059 B MX362059 B MX 362059B
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- carbamate
- urea derivatives
- medicaments
- medicament
- Prior art date
Links
- 150000004657 carbamic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 241000289669 Erinaceus europaeus Species 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012078933 | 2012-07-20 | ||
| CN2013078309 | 2013-06-28 | ||
| PCT/IB2013/055916 WO2014013469A1 (en) | 2012-07-20 | 2013-07-18 | Carbamate/urea derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000903A MX2015000903A (es) | 2015-04-10 |
| MX362059B true MX362059B (es) | 2019-01-07 |
Family
ID=49263333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000903A MX362059B (es) | 2012-07-20 | 2013-07-18 | Derivados de carbamato/urea. |
Country Status (41)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201321353A (zh) | 2011-10-08 | 2013-06-01 | Novartis Ag | 胺基甲酸酯／尿素衍生物 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| EP3391886A1 (en) | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| BR112021006366A2 (pt) | 2018-10-11 | 2021-07-06 | Novartis Ag | uso de um agonista inverso h3r para o tratamento de sonolência diurna excessiva associada à doença de parkinson (dp) |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| TW301607B (en:Method) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| ATE327230T1 (de) | 2000-01-20 | 2006-06-15 | Eisai Co Ltd | Piperidinverbindungen und diese enthaltenden medikamente |
| CN1298715C (zh) | 2001-03-13 | 2007-02-07 | 先灵公司 | 作为组胺h3拮抗剂的非咪唑化合物 |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7592347B2 (en) | 2003-04-23 | 2009-09-22 | Glaxo Group Limited | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases |
| EP1717230B1 (en) | 2004-02-13 | 2014-08-06 | Msd K.K. | Fused-ring 4-oxopyrimidine derivative |
| SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| EP1784398A1 (en) | 2004-09-02 | 2007-05-16 | Teva Pharmaceutical Industries Ltd | Purification of olmesartan medoxomil |
| CN1993355A (zh) | 2004-09-02 | 2007-07-04 | 特瓦制药工业有限公司 | 奥美沙坦酯的纯化方法 |
| JP2009506987A (ja) * | 2005-08-02 | 2009-02-19 | ニューロゲン コーポレイション | ジピペラジニルケトンおよび関連する類似体 |
| WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| BRPI0820950A2 (pt) * | 2007-12-05 | 2015-07-07 | Astrazeneca Ab | Composto, formulação farmacêutica, uso de um composto, métodos para o tratamento ou prevenção de condições ou doenças e para inibição da angiogênese, e, processo para a preparação de um composto. |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2011090062A1 (ja) | 2010-01-22 | 2011-07-28 | 大鵬薬品工業株式会社 | Pgds阻害作用を有するピペラジン化合物 |
| TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| TW201321353A (zh) * | 2011-10-08 | 2013-06-01 | Novartis Ag | 胺基甲酸酯／尿素衍生物 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2013
- 2013-07-17 US US13/944,354 patent/US9034874B2/en active Active
- 2013-07-18 MY MYPI2014003308A patent/MY168752A/en unknown
- 2013-07-18 AU AU2013291617A patent/AU2013291617B2/en not_active Ceased
- 2013-07-18 CA CA2878006A patent/CA2878006C/en active Active
- 2013-07-18 JP JP2015522234A patent/JP6203841B2/ja not_active Expired - Fee Related
- 2013-07-18 RS RS20171048A patent/RS56479B1/sr unknown
- 2013-07-18 KR KR1020157001045A patent/KR102150739B1/ko not_active Expired - Fee Related
- 2013-07-18 EP EP13770709.7A patent/EP2875016B1/en active Active
- 2013-07-18 PL PL13770709T patent/PL2875016T3/pl unknown
- 2013-07-18 SG SG10201700188PA patent/SG10201700188PA/en unknown
- 2013-07-18 NO NO13770709A patent/NO2875016T3/no unknown
- 2013-07-18 CU CUP2015000006A patent/CU24248B1/es unknown
- 2013-07-18 CN CN201380038422.1A patent/CN104470911B/zh not_active Expired - Fee Related
- 2013-07-18 MX MX2015000903A patent/MX362059B/es active IP Right Grant
- 2013-07-18 PT PT137707097T patent/PT2875016T/pt unknown
- 2013-07-18 WO PCT/IB2013/055916 patent/WO2014013469A1/en active Application Filing
- 2013-07-18 IN IN10449DEN2014 patent/IN2014DN10449A/en unknown
- 2013-07-18 HU HUE13770709A patent/HUE035592T2/en unknown
- 2013-07-18 ES ES13770709.7T patent/ES2648512T3/es active Active
- 2013-07-18 BR BR112015001207-8A patent/BR112015001207B1/pt not_active IP Right Cessation
- 2013-07-18 EA EA201590250A patent/EA026091B1/ru not_active IP Right Cessation
- 2013-07-18 SG SG11201408020RA patent/SG11201408020RA/en unknown
- 2013-07-18 DK DK13770709.7T patent/DK2875016T3/da active
- 2013-07-18 NZ NZ702346A patent/NZ702346A/en not_active IP Right Cessation
- 2013-07-18 LT LTEP13770709.7T patent/LT2875016T/lt unknown
- 2013-07-18 HR HRP20171692TT patent/HRP20171692T1/hr unknown
- 2013-07-18 AP AP2014008109A patent/AP3710A/en active
- 2013-07-18 PE PE2015000045A patent/PE20151155A1/es active IP Right Grant
- 2013-07-18 SI SI201330787T patent/SI2875016T1/sl unknown
- 2013-07-19 TW TW102125975A patent/TWI597276B/zh not_active IP Right Cessation
- 2013-07-19 UY UY0001034921A patent/UY34921A/es unknown
- 2013-07-21 JO JOP/2013/0218A patent/JO3439B1/ar active
- 2013-07-22 AR ARP130102583A patent/AR092354A1/es active IP Right Grant
-
2014
- 2014-11-27 ZA ZA2014/08805A patent/ZA201408805B/en unknown
- 2014-11-28 TN TN2014000497A patent/TN2014000497A1/fr unknown
- 2014-12-05 PH PH12014502743A patent/PH12014502743B1/en unknown
-
2015
- 2015-01-09 CL CL2015000056A patent/CL2015000056A1/es unknown
- 2015-01-11 IL IL236656A patent/IL236656A/en active IP Right Grant
- 2015-01-20 CR CR20150019A patent/CR20150019A/es unknown
- 2015-01-20 GT GT201500012A patent/GT201500012A/es unknown
- 2015-01-20 CO CO15009915A patent/CO7170173A2/es unknown
- 2015-04-14 US US14/685,926 patent/US9273026B2/en active Active
-
2016
- 2016-02-22 US US15/049,739 patent/US9624192B2/en active Active
-
2017
- 2017-03-07 US US15/452,430 patent/US20170275264A1/en not_active Abandoned
- 2017-10-25 CY CY20171101112T patent/CY1119492T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015000903A (es) | Derivados de carbamato/urea. | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
| PH12014500987A1 (en) | Neprilysin inhibitors | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| NZ748946A (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MY172924A (en) | Neprilysin inhibitors | |
| PH12013500473A1 (en) | Triazine-oxadiazoles | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| MX2013006802A (es) | Inhibidores de neprilisina. | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| IN2015DN03998A (en:Method) | ||
| MX364400B (es) | Compuestos de tetraciclina. | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| HK1201839A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands | |
| PH12015500373A1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| HK1202116A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands | |
| TN2013000089A1 (en) | Triazine-oxadiazoles | |
| HK1231074A1 (en) | Neprilysin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |